论文部分内容阅读
目的探讨强脾益气方联合替吉奥治疗晚期胃癌患者的疗效。方法选取2013年1月至2015年1月间收治的晚期胃癌患者150例,按照随机数字表法分为实验组和对照组,每组75例。实验组患者采用替吉奥联合健脾益气方治疗,对照组患者给予替吉奥化疗。比较两组患者疗效、恶心及骨髓抑制情况。结果实验组患者部分缓解率明显高于对照组,实验组患者总有效率和疾病控制率较高,差异均有统计学意义(P<0.05)。实验组患者轻度恶心发生率明显高于对照组,重度恶心发生率低于对照组,差异有统计学意义(P<0.05)。实验组患者0度骨髓抑制发生率高于对照组,Ⅱ度骨髓抑制发生率低于对照组,差异有统计学意义(P<0.05),两组患者Ⅰ度和Ⅲ度骨髓抑制发生率差异无统计学意义(P>0.05)。结论强脾益气方联合替吉奥治疗方案可以明显提高晚期胃癌患者的疗效,减轻其恶心、骨髓抑制等不良反应。
Objective To investigate the therapeutic effect of Qiangpien Yiqi combined with tigiao on patients with advanced gastric cancer. Methods 150 patients with advanced gastric cancer who were admitted between January 2013 and January 2015 were divided into experimental group and control group according to the random number table method, with 75 cases in each group. Patients in the experimental group were treated with TIGO combined with Jianpi Yiqi prescription, and patients in the control group were given TIGO chemotherapy. Efficacy, nausea and bone marrow suppression were compared between the two groups. Results The partial remission rate in experimental group was significantly higher than that in control group. The total effective rate and disease control rate in experimental group were significantly higher (P <0.05). The incidence of mild nausea in the experimental group was significantly higher than that in the control group, the incidence of severe nausea was lower than that in the control group, the difference was statistically significant (P <0.05). The incidence of myelosuppression at 0 degree in the experimental group was higher than that of the control group, and the incidence of grade Ⅱ myelosuppression was lower than that of the control group (P <0.05). There was no difference in the incidence of grade Ⅰ and Ⅲ myelosuppression between the two groups Statistical significance (P> 0.05). Conclusion Qiangpi Yiqi combined with tigiao treatment can significantly improve the efficacy of patients with advanced gastric cancer and reduce its nausea, bone marrow suppression and other adverse reactions.